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Abstract
Background: There is scant information on whether Human Immunodeficiency Virus (HIV) seropositivity has an 
influence on the outcome of treatment of precancerous cervical lesions using cryotherapy. We studied the prevalence 
of cervical abnormalities detectable by visual inspection and cervical lesions diagnosed by colposcopy according to 
HIV serostatus and described the outcomes of cryotherapy treatment.
Methods: Trained nurses examined women not previously screened for cervical cancer using visual inspection with 
acetic acid (VIA) and Lugol's iodine (VILI) in two family planning/post natal clinics in Kampala, Uganda, from February 
2007 to August 2008. Women with abnormal visual inspection findings were referred for colposcopic evaluation and 
HIV testing. Women with precancerous cervical lesions detected at colposcopy were treated mainly by cryotherapy, 
and were evaluated for treatment outcome after 3 months by a second colposcopy.
Results: Of the 5 105 women screened, 834 presented a positive screening test and were referred for colposcopy. Of 
these 625 (75%) returned for the colposcopic evaluation and were tested for HIV. For the 608 (97.5%) women in the age 
range 20-60 years, colposcopy revealed 169 women with cervical lesions: 128 had inflammation, 19 had low grade 
squamous intraepithelial lesion (LGSIL), 13 had high grade squamous intraepithelial lesion (HGSIL), 9 had invasive 
cervical cancer and 2 had inconclusive findings. Detection rates per 1 000 women screened were higher among the 
older women (41-60 years) compared to women aged 20-40 years. They were accordingly 55% and 20% for 
inflammation, 10% and 2% for LGSIL, 5% and 2% for HGSIL, 6% and 1% for invasive cervical cancer.
Of the 608 women, 103 (16%) were HIV positive. HIV positivity was associated with higher likelihood of inflammation
(RR = 1.7; 95% CI: 1.2-2.4).
Conclusions: Detection rates were higher among older women 41-60 years. Visual inspection of the cervix uteri with 
acetic acid (VIA) and Lugol's iodine (VILI) used as a sole method for cervical cancer screening would entail significant 
false positive results. HIV seropositivity was associated with a higher prevalence of inflammatory cervical lesions. In 
view of the small numbers and the relatively short follow up time of 3 months, we could not make an emphatic 
conclusion about the effect of HIV serostatus on cryotherapy treatment outcome.
Background
Cervical cancer is the second most common cancer
among females worldwide, accounting for 452 000 new
patients per year. It is the most common female cancer in
sub-Saharan Africa alone and 57 000 estimated new cases
of cervical cancer occurred in the year 2000, comprising
22% of all cancers [1]. In Uganda, cervical cancer is the
most common female cancer with an estimated age stan-
dardized incidence rate of 40.7 per 100 000 [2].
The incidence of squamous cell carcinoma of the cervix
has declined in the high income countries over time
largely due to effective screening services using the Pap
smear [3-5]. Such programs which use cytological screen-
ing are too expensive both materially and at the organiza-
tional level for most low income countries [6,7]. A
situational analysis of cervical cancer screening services
in 5 countries in eastern, central and southern Africa
including Uganda, found insufficient cervical cancer
screening services at most health units [8]. In a few coun-
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tries where they exist, scant information on evaluation of
the programs is available.
Persistent cervical infection with high risk human pap-
illomavirus (HPV) has been established as the necessary
cause of cervical cancer [9,10].
Several studies have demonstrated an increased risk of
invasive cervical cancer among HIV positive women.
Also the US Centers for Disease Control and Prevention
included cervical cancer as one of the AIDS defining ill-
nesses [11]. However some studies, in particular in sub-
Saharan Africa, have found no association between HIV
seroprevalence and invasive cervical cancer [12-15].
Competing risk of mortality from other conditions asso-
ciated with HIV has been suggested as a possible explana-
tion for this lack of consistency [14]. Similar sexual
behavioural factors predispose individuals in acquiring of
both HPV and HIV. The immunosuppressive effects of
HIV has been reported to contribute to multiple HPV
infections [16], persistence of high risk HPV infections
[17], and the progression of HPV induced neoplastic cer-
vical changes [18-22].
Uganda has succeeded in reducing HIV prevalence sub-
stantially in the last decade from 15-30% in 1992 [23] to
currently 5-8% in the general population, with uneven
distribution among men (5%) and women (8%) aged 15-
49 years [24].
Guidelines on cervical cancer screening among HIV
positive women differ from country to country. For newly
diagnosed HIV positive women most developed coun-
tries recommend two screening tests with a six month
interval, followed by annual screening [25,26]. The feasi-
bility of such a strategy is doubtful for poor countries in
particular because of difficulties in follow-up of patients.
Recent evidence indicates that immunosuppression, as
evidenced by reduced CD4 counts - and not HIV positiv-
ity per se - is responsible for the HPV persistent infection,
recurrence and rapid progression [27,28]. The increasing
availability of antiretroviral treatments will have implica-
tions for the screening and treatment regimens for cervi-
cal precancerous lesions among HIV seropositive
women, but these are so far undocumented in sub-Saha-
ran Africa. Information is required to develop feasible
guidelines for poor countries, such as Uganda, where the
prevalence of both HIV and cervical cancer is high.
Despite the great promise of the newly developed HPV
vaccines, availability of HPV vaccines will not negate the
need for screening [29]. Since cytology based screening is
not feasible in low resource countries like Uganda, alter-
native screening methods have been suggested. A recent
study from India showed significant reduction from cer-
vical cancer deaths by single HPV testing followed by
treatment [30]. Though superior, HPV DNA screening is
still relatively expensive and in the poorer countries less
costly screening methods such as visual inspection with
acetic acid (VIA) in 'see and treat' strategies may remain
the only available and feasible method for the near future.
Visual inspection has been found to be safe and accept-
able when performed by nurses [31] although its impact
in preventing advanced cervical lesions is still controver-
sial with specificity consistently reported as lower than
cytology. This is a situation that may lead to over diagno-
sis and over treatment [32].
We present results from a see-see and treat cervical
screening program in Uganda, describing the prevalence
of cervical lesions as diagnosed by colposcopy, detection
rates by age group and the outcome of the cervical lesion
treatment using cryotherapy.
Methods
Setting and screening routine
The study was carried out in Mulago, the national referral
and teaching hospital in Uganda, a country where so far
only opportunistic cervical cancer screening is offered in
very few centres mainly using visual inspection. Two fam-
ily planning/postnatal clinics that are run by nurses/mid-
wives were the primary health care facilities. The 9 nurses
participating in this study had experience on use of the
vaginal speculum since they used it routinely for inserting
intrauterine contraceptive devices; they were intensively
trained for a period of one month by a gynaecologist on
screening using visual inspection with acetic acid and
Lugol's iodine. Special emphasis was made on recognition
of the squamo-columnar junction, the transformation
zone, acetowhitening and colour changes resulting from
application of Lugol's iodine. A gynaecologist was always
available in the clinics throughout the study period for
consultation whenever the nurses were uncertain about
their findings. At the beginning of each day when the cli-
ents were assembled, group health education sessions
were held about the available reproductive health ser-
vices. The education included relevant information about
the extent of the problem of cervical cancer, causes and
risk factors, symptoms of the disease and treatment
options. Lastly and in detail, they were educated on the
prevention of the cancer including the details of the avail-
able screening procedure. At the end those who were eli-
gible for screening were offered the screening test.
Women, who were not currently menstruating, were not
pregnant, who had never been screened for cervical can-
cer before and had no history of hysterectomy were eligi-
ble for screening in the study. Eligible women were then
informed of the study in detail and a signed informed
consent was obtained from those who agreed to partici-
pate in the study. A structured interview using a ques-
tionnaire was performed by the nurses, including
information on education, socioeconomic status, repro-
ductive and medical history. The visual screening was
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acid to the cervix. After one minute, the nurse inspected
the cervix for acetowhitening in the transformation zone
close to the squamocolumnar junction. If there was no
acetowhitening, it would be regarded as a negative test. If
there was acetowhitening, the nurse would then apply
Lugol's iodine and observe the colour changes. A normal
cervix would turn mahogany brown. Non uptake or mus-
tard yellow colouring would imply an abnormality. The
nurse would inform the woman about the visual inspec-
tion findings, and those with a positive screening test
would be referred for colposcopy after a week. This to
allow a few days (3-5) for Lugol's iodine to disappear from
the cervix, which would otherwise obscure the vision of
cervical vasculature and the acetowhitening which is
essential in colposcopic evaluation. The work of the
nurses was supervised and monitored by a trained
gynaecologist.
HIV testing
All women who returned for the colposcopic examina-
tion were tested for HIV. We used the Abbott Determine
HIV-1/2 qualitative immunochromatographic test manu-
factured by Abbot Japan co., ltd, Minato-Ku, Tokyo,
Japan. Test results were validated using 2 other tests: The
ChemBio HIV 1/2 Sta-Pak Dipstick, manufactured by
ChemBio Diagostics Systems, Inc., 3661 Horseblock
Road, Medford, NY 11763, USA, and The Trinity Biotech
Uni-Gold HIV Test manufactured By Trinity Biotech Plc,
Bray Co Wicklow, Ireland. The women had been
informed about the HIV testing prior to their accepting
to participate in the study. Post test counselling was done
and where necessary women were directed to the rele-
vant clinics that offer HIV care services.
Colposcopic evaluation and treatment of lesions
Blind to the HIV status of the woman, colposcopy was
d o n e  b y  t h e  s a m e  i n v e s t i g a t o r  w h o  g r a d e d  t h e  l e s i o n s
using the Reids colposcopic index [33]. The index consid-
ers 4 colposcopic signs; lesion margin, colour of ace-
towhitening, blood vessels and iodine staining. It permits
objective differentiation between squamous intraepithe-
lial neoplasm (SIL) as low-grade cervical lesions (LGSIL)
and high-grade lesions (HGSIL). Use of the index helps
direct the clinician to perform a biopsy of the most signif-
icant abnormal cervical lesions. Findings were recorded
on a scale of increasing severity as: normal, inflammation,
atypia/CIN/condylomata/wart/leukoplakia/HPV change,
CIN2-3, invasive carcinoma or inconclusive.
After taking a colposcopic guided biopsy, precancerous
lesions were treated immediately using cryotherapy or
LEEP if the lesion extended over more than 75% of the
transformation zone. The cryotherapy used nitrous oxide
gas. All women who were treated were given a course of
antibiotics, (Metronidazole and Doxycycline) for a week.
We did not take biopsies from the cervix that appeared
normal on colposcopy or where the colposcopist was
convinced the diagnosis was inflammation. Punch biopsy
has its own complications and we did not want to expose
the women to any added morbidity. The women were told
to come back for re-evaluation after 3 months. However,
they could come back earlier if they experienced compli-
cations like bleeding or persistent foul smelling vaginal
discharge. Those who had other cervical conditions like
infections were appropriately treated and those with cer-
vical polyps or obvious cancer were admitted to the
gynaecological ward for appropriate management.
Follow up evaluation
The women who had precancerous lesions and were
treated had a colposcopic re-evaluation after 3 months by
the same colposcopist to assess the outcome of treatment
i.e. persistent lesions, infection/inflammation, and cervi-
cal stenosis. The information was duly recorded on their
data forms and women informed of the findings.
Data analysis
We described the demographic characteristics of the
women who were screened. We described the VIA/VILI
test results and compliance with referral for colposcopy.
We report on the HIV serostatus of the women who
returned for colposcopy. We computed the detection
rates by age group per 1 000 women screened, basing it
on the colposcopy diagnosis. We did not use the histology
results in the analysis as we had not taken biopsies where
colposcopy diagnosis was normal or an inflammation,
due to ethical reasons. The computation of detection
rates was done for women between 20-60 years of age
since no lesions were found among women outside this
age bracket, since they were only 2.5% of the total. The
software Stata version 10 was used for all the data analy-
ses.
Ethical considerations
The study was cleared by the institutional review board of
Makerere Medical School and the National Council for
Science and Technology. During the study period, the
screening service was offered to all eligible women, even
those who declined to participate in the study. Those who
participated in the study gave a written informed consent.
All women were clearly informed that if they did not
desire to participate in the study they would receive the
same care, and if participating that they could withdraw
their participation at any time; and that their eventual
withdrawal would not affect treatment. All screening and
treatment was free of any cost to the patient except the
transportation costs of returning for the colposcopy visit,
which they themselves had to meet.Mutyaba et al. Reproductive Health 2010, 7:4
http://www.reproductive-health-journal.com/content/7/1/4
Page 4 of 9
Results
Altogether 5 105 women were screened between Febru-
ary 2007 and August 2008. Follow up was up to 30th
November 2008. The flow of women into the study is
summarized in Figure 1. The demographic characteristics
of the women screened are summarised in Table 1. The
majority of women screened (97.5%) were between 20-60
years of age. 70% had started sex before 20 years of age,
16% had had more than 5 pregnancies. 95% had achieved
at least primary school education. Only 24% could be
considered high income earners.
A positive visual inspection screening test was found in
834 (16%) of the women and they were referred for col-
poscopy. VIA positivity was 11% whereas VILI positivity
was 13%. Of the women referred for colposcopy, 13 were
less than 20 years of age and 12 were over 60 years of age.
The majority (809) were between 20-60 years.
Of the 834 women referred for colposcopy, 209 (25%)
did not return for colposcopy. 625 women returned for
the colposcopic evaluation and were tested for HIV, and
103 (16%) were HIV positive. See Table 2.
Of the 625 colposcopied women 608 (97.3%) were
between 20-60 years of age and were the ones included in
the analysis of detection rates. One hundred and sixty
nine (169) women had cervical lesions: 128, inflamma-
tion; 19, LGSIL; 13, HGSIL; 9, invasive cancer. Including
colposcopic diagnosis of inflammation, the false positive
screening by visual inspection alone, calculated as the
proportion of women with a positive visual inspection
but a negative colposcopy, was 72% (439 out of 608).
Detection rates of the different cervical lesions were
higher among women aged 41-60 years compared to
younger women aged 20-40 years (Table 3). Respectively,
they were 55 per 1 000 and 20 per 1 000 for inflammation,
10 per 1 000 and 2 per 1 000 for LGSIL, 5 per 1 000 and 2
per 1 000 for HGSIL, 6 per 1 000 and 1 per 1 000 for inva-
sive cervical cancer.
The 32 women with SIL (19 LGSIL and 13 HGSIL)
underwent treatment by cryotherapy (31 women) or
LEEP (1 woman). After three months of treatment a new
colposcopy was carried out among the women who had
been treated with cryotherapy: 1 woman had persistent
LSIL and 1 had inflammation; both were HIV positive.
Two women, both HIV negative, did not return after 3
months. All other 27 women had normal findings. There
was no difference in the treatment outcomes of the HIV
positive and HIV negative women after 3 months.
Discussion
Our study found a high prevalence of HIV among the
women referred for colposcopy after positive screening
using visual inspection. Inflammation of the cervix uteri
and low grade cervical lesions were significantly associ-
ated with HIV seropositivity. False positivity by visual
inspection was high considering colposcopy diagnosis to
be correct.
The study had some limitations. Biopsies were not
taken when colposcopy results were considered normal
or inflammation only, as we did not desire to add morbid-
ity. Moreover, the study aimed to simulate conditions as
they would be in a non-study situation of service provi-
sion. However, colposcopy tends to overestimate severity
of lesions. We used only the colposcopy diagnosis in the
analysis and thus might have overestimated the severity
of the cervical lesions since colposcopy is not the gold
standard of diagnosis [34].
The nurses were newly trained in screening using visual
inspection. Though their skills improved over time, they
had initial problems especially with accepting cervical
ectopy as a normal finding. This contributed to the high
false positivity at screening. Because of limitation of time
and resources, the study ended before we could accumu-
late enough numbers to have enough power to emphati-
cally study the effect of HIV seropositivity on treatment
outcomes using cryotherapy.
Among women screened positive at visual inspection
and referred for colposcopy, HIV prevalence at 16% was
double that of the general Ugandan women population
aged 15-49 years [14]. The higher HIV prevalence among
women referred for colposcopy may imply that detectable
cervical lesions using VIA/VILI are more prevalent
among HIV positive women, or that a higher proportion
of HIV positive women attend the postnatal and family
planning clinics compared to the general population.
Others may have heard of the screening service and came
specifically for this. This may be true especially for those
who knew their HIV status prior to the study. Women in
Kampala who know their HIV status are usually more
health conscious and are more likely to come for postna-
tal care and also to seek contraception [35].
Prevalence of inflammation was significantly higher
among HIV positive women compared to HIV negative
women. Of the 9 women with invasive cancer, 8 were HIV
negative. Because of the very small numbers of lesions,
we could not establish statistical associations between the
different lesions and HIV serostatus or other explanatory
variables. The findings of high prevalence of inflamma-
tion were expected, since other sexually transmitted
infections causing cervical inflammation would lead to
more false positive screening. The interaction between
HIV and other sexually transmitted diseases of the repro-
ductive health tract have been reported to be synergistic
[36,37]. We didn't do biopsy lesions where the colposco-
pist diagnosed an inflammation (i.e. no precancerous
lesion), therefore few lesions classified as inflammation
may have been low grade precancerous lesions. Still the
high HIV prevalence among the women referred for col-Mutyaba et al. Reproductive Health 2010, 7:4
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5 105 women screened by midwives                      VIA/VILI negative - Home 
using VIA/VILI.  
            
 
 
834 VIA/VILI positive (Referred for colposcopy)     209 Did not return for colposcopy 
            
 
 
625 Returned (HIV positive = 103; HIV negative = 522)  
            
 
 
Colposcopy evaluation.        454 Negative colposcopy - Home  
        171 had positive colposcopy  
        9 invasive cervical cancer - to hospital for treatment 
        128 inflammation, treated - antibiotics/antifungal for infection 
        32 SIL (19-LGSIL, 13-HGSIL)                                                       
      
 
 
Colposcopically directed biopsy                         
Treatment  31 had cryotherapy, 1 LEEP                               
 Follow-up after 3 months by colposcopic evaluation: 
- 27 were colposcopy negative  
- 1 had inflammation, 1 persistent LGSIL, both HIV positive 
- 3 did not return, all HIV negative 
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< 20 92 1.8
20-40 4 119 80.7
41-60 860 16.9
> 60 34 0.7
Total 5 105 100
Education
Inst/University 1 613 31.6
Secondary 1 869 36.6
Primary 1 385 27.1
Nil/Unknown 238 4.7
Total 5 105 100
Income status
High 1 198 23.5
Medium 1 460 28.6
Low 2 447 47.9
Total 5 105 100
Residence
Urban 4 475 87.7
Rural 630 12.3
Total 5 105 100
Onset of sex
< 20 years of age 3 608 70.7
≥ 20 years of age 1 497 29.3
Total 5 105 100
Total pregnancies
> 5 795 15.6
≤ 5 4 310 84.4
Total 5 105 100
Distance from Mulago
≤ 10 km 4 112 80.5
> 10 km 993 19.5
Total 5 105 100
poscopy would most likely imply a high prevalence of
STDs and therefore cervicitis.
Cervical precancerous lesions are known to take years
to progress. Luciani et al. [38] in a see and treat program
in Peru found that cryotherapy was effective and cheap in
treatment of precancerous lesions and could be used by
low level health workers. They reviewed the patients after
1 year and found cure rates as high as 88% in all CIN and
70% for baseline diagnosis of CIN3. We had similarly
good results after cryotherapy. Only 2 women (both HIV
positive) had lesions on review after 3 months. 27 (20
HIV negative and 7 HIV positive) had no evidence of dis-
ease. However in view of the small numbers and the rela-
tively short follow up time of 3 months, we could not
make an emphatic conclusion about the effect of HIV
serostatus on treatment outcome.





Negative 4 538 88.9
Total 5 105 100
VILI result
Positive 664 13.0
Negative 4 441 87.0
Total 5 105 100
Referral for colposcopy
Referred 834 16.3
Not referred 4 271 83.7
Total 5 105 100
Compliance with referral
Returned for colposcopy 625 75.0
Did not return for colposcopy 209 25.0
Total 834 100
HIV status (women who returned for colposcopy)
Positive 103 16.5
Negative 522 83.5
Total 625 100Mutyaba et al. Reproductive Health 2010, 7:4
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Considering colposcopy diagnosis as correct, we had
very high false positive results of visual inspection
through screening by the nurses. Out of the 608 women
aged 20-60 years visually considered as positive, only 169
were colposcopically diagnosed with cervical lesions even
though 128 of these were inflammation. Assuming that
all the 169 women had dysplasia, it would mean that only
27.8% of the women should have been positive, which
denotes a false positivity of the visual screening of at least
72%. The nurses were instructed to error on the positive
side, so as minimize false negative screening as much as
possible. Another possible reason for the high false posi-
tivity was the large number of women who had ectopy.
This is quite confusing to the inexperienced nurses espe-
cially with use of Lugol's iodine when screening. Since 9
nurses were involved in our study, it was not possible for
all of them to have attained the same level of skill. The
findings of a high false positivity rate have implications
for see and treat screening programs. Whereas some
advocate treatment with cryotherapy after a positive VIA
test ('see and treat'), others advocate for cryotherapy after
VIA and positive colposcopy ('see-see and treat'). If we
had adopted the first one, we would have over treated by
72% (439 out of 625). This has implications of side effects
of treatment like cervical stenosis and sometimes incom-
petence, infections and persistent discharge. In this study
where many women had inflammation, cryotherapy
would have added to significant morbidity. Over treat-
ment in 'see and treat' strategies has been noted to range
between 1.2-83.3% for LGSIL and 12.3-83.3% for HGSIL.
With use of colposcopy over treatment could be brought
down to less than 30% overall [39]. There is evidence that
nurses can be trained effectively as colposcopists [40-42].
It would be advisable to incorporate this colposcopy
training in the 'see and treat' strategies for cervical cancer
prevention. In the absence of colposcopists, it is impera-
tive to ensure very intensive and continuous training for
the nurses and close supervision so as to minimize over
treatment.
Detection rates per 1 000 women screened were higher
among the older women (41-60) years compared to
younger women aged 20-40 years. This has implications
for screening programs in low resource settings. With the
few available resources, it would be wiser to target
women at least above 30 years of age. A high loss to fol-
low up of 25% means policy planners need to devise pro-
grams where the colposcopy and treatment is done the
same day as the screening. Currently in Uganda cervical
cancer prevention has at long last received the political
attention long overdue. In addition to the above program
in Mulago, there is an effort to roll out screening to other
parts of the country, using visual inspection. In some of
the programs, see and treat strategy is being used. Our
findings will influence the need to invest in colposcopy
training so as to adopt the see-see and treat strategy.
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